Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth
Authors
Keywords
Ewing sarcoma, Sp1, Survivin, Tolfenamic acid, Mithramycin, Targeted therapy
Journal
INVESTIGATIONAL NEW DRUGS
Volume 35, Issue 2, Pages 158-165
Publisher
Springer Nature
Online
2016-12-26
DOI
10.1007/s10637-016-0417-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of murine breast cancer growth and metastasis by survivin-targeted siRNA using disulfide cross-linked linear PEI
- (2016) Shan Liu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus
- (2016) Zakir Khan et al. RADIOTHERAPY AND ONCOLOGY
- Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone
- (2016) Vickie Y. Jo et al. Surgical Oncology Clinics of North America
- Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients
- (2016) Jiong Hu et al. Oncotarget
- Sp1 and the ‘hallmarks of cancer’
- (2015) Kate Beishline et al. FEBS Journal
- Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
- (2015) Shuang Yan et al. Oncotarget
- WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition
- (2013) Vickie Y. Jo et al. PATHOLOGY
- Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study
- (2013) Don Eslin et al. TUMOR BIOLOGY
- Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model
- (2012) Eun-Sun Choi et al. CANCER LETTERS
- BIRC5 expression is a poor prognostic marker in Ewing sarcoma
- (2012) Pooja Hingorani et al. PEDIATRIC BLOOD & CANCER
- Survivin, a target to modulate the radiosensitivity of Ewing’s sarcoma
- (2012) B. Greve et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Interplay of Posttranslational Modifications in Sp1 Mediates Sp1 Stability during Cell Cycle Progression
- (2011) Yi-Ting Wang et al. JOURNAL OF MOLECULAR BIOLOGY
- Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening
- (2011) Patrick J. Grohar et al. JNCI-Journal of the National Cancer Institute
- Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma
- (2011) Don Eslin et al. MOLECULAR CARCINOGENESIS
- Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met
- (2009) S. Papineni et al. CARCINOGENESIS
- Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression
- (2009) S. Konduri et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search